CN102355907A - 用苯达莫司汀和抗cd20抗体的组合治疗癌症 - Google Patents

用苯达莫司汀和抗cd20抗体的组合治疗癌症 Download PDF

Info

Publication number
CN102355907A
CN102355907A CN2010800123232A CN201080012323A CN102355907A CN 102355907 A CN102355907 A CN 102355907A CN 2010800123232 A CN2010800123232 A CN 2010800123232A CN 201080012323 A CN201080012323 A CN 201080012323A CN 102355907 A CN102355907 A CN 102355907A
Authority
CN
China
Prior art keywords
bendamustine
antibody
antibodies
described method
lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800123232A
Other languages
English (en)
Chinese (zh)
Inventor
C.T.托马斯
G.钱
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of CN102355907A publication Critical patent/CN102355907A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2010800123232A 2009-01-16 2010-01-15 用苯达莫司汀和抗cd20抗体的组合治疗癌症 Pending CN102355907A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14521009P 2009-01-16 2009-01-16
US61/145,210 2009-01-16
PCT/US2010/021123 WO2010083365A1 (en) 2009-01-16 2010-01-15 Treatment of a cancer using a combination of bendamustine and an anti-cd20 antibody

Publications (1)

Publication Number Publication Date
CN102355907A true CN102355907A (zh) 2012-02-15

Family

ID=42340093

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800123232A Pending CN102355907A (zh) 2009-01-16 2010-01-15 用苯达莫司汀和抗cd20抗体的组合治疗癌症

Country Status (13)

Country Link
US (1) US20110274697A1 (2)
EP (1) EP2405937A4 (2)
JP (1) JP2012515217A (2)
KR (1) KR20110111303A (2)
CN (1) CN102355907A (2)
AU (1) AU2010204666A1 (2)
BR (1) BRPI1006829A2 (2)
CA (1) CA2749151A1 (2)
EA (1) EA201170940A1 (2)
IL (1) IL213794A0 (2)
MX (1) MX2011007589A (2)
SG (1) SG172792A1 (2)
WO (1) WO2010083365A1 (2)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110121338A (zh) * 2016-07-13 2019-08-13 武田药品工业株式会社 脾酪氨酸激酶抑制剂和其他治疗剂的组合
WO2019228406A1 (en) * 2018-05-29 2019-12-05 Wuxi Biologics (Shanghai) Co., Ltd. A novel anti-cd3/anti-cd20 bispecific antibody
CN110540593A (zh) * 2018-05-29 2019-12-06 无锡智康弘义生物科技有限公司 新型的抗cd3/抗cd20双特异性抗体
WO2024179545A1 (zh) * 2023-03-01 2024-09-06 上海津曼特生物科技有限公司 包含cd20/cd47阻断双功能融合蛋白的联合用药物及其用途
WO2024263798A1 (en) * 2023-06-20 2024-12-26 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating prostate cancer
WO2024263801A3 (en) * 2023-06-20 2025-03-27 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating ovarian cancer
WO2024263804A3 (en) * 2023-06-20 2025-03-27 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating kidney cancer
WO2024263813A3 (en) * 2023-06-21 2025-04-10 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating colorectal cancer

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI409079B (zh) * 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2013120302A (ru) 2010-10-01 2014-11-20 Модерна Терапьютикс, Инк. Сконструированные нуклеиновые кислоты и способы их применения
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
PL2744515T3 (pl) * 2011-08-16 2022-05-30 Morphosys Ag Terapia skojarzona przeciwciałem anty-cd19 i iperytem azotowym
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
FR2980110A1 (fr) * 2011-09-20 2013-03-22 Lfb Biotechnologies Combinaison d'anticorps anti-cd20 et de bendamustine
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
CN104114572A (zh) 2011-12-16 2014-10-22 现代治疗公司 经修饰的核苷、核苷酸和核酸组合物
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
AU2013243948A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
WO2014081507A1 (en) 2012-11-26 2014-05-30 Moderna Therapeutics, Inc. Terminally modified rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
JP2022508807A (ja) 2018-10-16 2022-01-19 ユーエス・ナノ・フード・アンド・ドラッグ・インコーポレーテッド 腫瘍内注射製剤
US11752165B2 (en) * 2020-04-13 2023-09-12 US Nano Food & Drug, Inc Basic chemotherapeutic intratumour injection formulation
EP4190352B1 (en) 2020-07-27 2026-03-25 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Formulation of novel bispecific anti-cd3/cd20 polypeptide complex
GB202218493D0 (en) * 2022-12-08 2023-01-25 Oncopeptides Ab Novel therapeutic combinations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080089885A1 (en) * 2006-10-10 2008-04-17 Vaccinex, Inc. Anti-cd20 antibodies and methods of use
US20080274120A1 (en) * 2005-11-10 2008-11-06 Topotarget Uk Limited Histone Deacetylase (Hdac) Inhibitors (Pxd101) for the Treatment of Cancer Alone or in Combination With Chemotherapeutic Agent

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101928344B (zh) * 2002-10-17 2014-08-13 根马布股份公司 抗cd20的人单克隆抗体
EP1844815B1 (en) * 2003-11-04 2011-09-14 Novartis Vaccines and Diagnostics, Inc. Combination therapy comprising anti-CD20 and anti-CD40 antibodies for the treatment of B cell-related cancers
WO2009083009A2 (en) * 2008-01-03 2009-07-09 Genmab A/S Monoclonal antibodies against cd32b

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080274120A1 (en) * 2005-11-10 2008-11-06 Topotarget Uk Limited Histone Deacetylase (Hdac) Inhibitors (Pxd101) for the Treatment of Cancer Alone or in Combination With Chemotherapeutic Agent
US20080089885A1 (en) * 2006-10-10 2008-04-17 Vaccinex, Inc. Anti-cd20 antibodies and methods of use

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110121338A (zh) * 2016-07-13 2019-08-13 武田药品工业株式会社 脾酪氨酸激酶抑制剂和其他治疗剂的组合
WO2019228406A1 (en) * 2018-05-29 2019-12-05 Wuxi Biologics (Shanghai) Co., Ltd. A novel anti-cd3/anti-cd20 bispecific antibody
CN110540593A (zh) * 2018-05-29 2019-12-06 无锡智康弘义生物科技有限公司 新型的抗cd3/抗cd20双特异性抗体
CN110540593B (zh) * 2018-05-29 2022-05-17 上海药明生物技术有限公司 新型的抗cd3/抗cd20双特异性抗体
WO2024179545A1 (zh) * 2023-03-01 2024-09-06 上海津曼特生物科技有限公司 包含cd20/cd47阻断双功能融合蛋白的联合用药物及其用途
WO2024263798A1 (en) * 2023-06-20 2024-12-26 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating prostate cancer
WO2024263801A3 (en) * 2023-06-20 2025-03-27 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating ovarian cancer
WO2024263804A3 (en) * 2023-06-20 2025-03-27 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating kidney cancer
WO2024263813A3 (en) * 2023-06-21 2025-04-10 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating colorectal cancer

Also Published As

Publication number Publication date
CA2749151A1 (en) 2010-07-22
WO2010083365A1 (en) 2010-07-22
US20110274697A1 (en) 2011-11-10
EP2405937A4 (en) 2012-06-20
JP2012515217A (ja) 2012-07-05
AU2010204666A1 (en) 2011-07-21
IL213794A0 (en) 2011-07-31
MX2011007589A (es) 2011-08-17
SG172792A1 (en) 2011-08-29
BRPI1006829A2 (pt) 2016-10-25
EA201170940A1 (ru) 2012-02-28
KR20110111303A (ko) 2011-10-10
EP2405937A1 (en) 2012-01-18

Similar Documents

Publication Publication Date Title
CN102355907A (zh) 用苯达莫司汀和抗cd20抗体的组合治疗癌症
JP6313825B2 (ja) 癌の治療のための抗−４−１ｂｂ抗体及びａｄｃｃ誘導抗体の組合せ
KR102158467B1 (ko) Ｉｉ형 항-ｃｄ20 항체와 선택적 ｂｃｌ-2 억제제와의 병용 치료요법
KR101278395B1 (ko) 항-ｂｃｌ-2 활성제와 유형 ⅱ 항-ｃｄ20 항체의 조합 요법
US20100111945A1 (en) Novel uses
KR20220097932A (ko) 항-pvrig 항체 제제 및 항-pd-1 항체를 사용한 병용 요법
JP2012521379A (ja) アフコシル化抗体と、ヒトｇｍ−ｃｓｆ、ヒトｍ−ｃｓｆ及び／又はヒトｉｌ−３から選択される１又は２以上のサイトカインとの組合せ療法
US20160090421A1 (en) Novel Uses
US12195547B2 (en) Dosing for combination treatment with anti-CD20/anti-CD3 bispecific antibody and anti-CD79B antibody drug conjugate
TW201808333A (zh) 使用奧法木單抗（ofatumumab）治療多發性硬化症之療程及方法
US20230014026A1 (en) Anti-Tumor Combination Therapy comprising Anti-CD19 Antibody and Polypeptides Blocking the SIRPalpha-CD47 Innate Immune Checkpoint
CN118103399A (zh) 喹啉衍生物与抗cd47抗体的药物组合
EP4410836A1 (en) Anti-cd47 antibody for combined treatment of blood tumor
CN120678937A (zh) 抗nkg2a抗体联合用药的新用途
WO2026061538A1 (zh) 用于治疗恶性肿瘤的抗pd-l1和抗4-1bb双特异性抗体及其药物组合
CN117940452A (zh) 用于治疗癌症的方法和组合物
HK40105342A (zh) 针对用抗cd20/抗cd3双特异性抗体和抗cd79b抗体药物缀合物进行组合治疗的给药
HK40045394A (en) Bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
WO2012121958A2 (en) Combination

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120215